There is no intervention in this study.
OtherThis study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
NCT Number: NCT00334750
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Pfizer Investigational Site, Calgary, Alberta, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Time frame: duration of study
Time frame: duration of study
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05181046
Eye Diseases, Glaucoma
Madurai, India
View Trial DetailsNCT04202562
Cardiovascular Diseases, Cataract
Madrid, Spain
View Trial DetailsNCT00051194
Eye Diseases, Glaucoma
Fort Worth, Texas, United States
View Trial DetailsNCT00311389
Eye Diseases, Glaucoma
Puurs, Belgium
View Trial Details